FlightPath Biosciences has filed a notice of an exempt offering of securities to raise $8 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, FlightPath Biosciences is raising $8,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Matthew Tindall played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About FlightPath Biosciences
Flightpath Biosciences uses advanced drug discovery tools to identify optimal therapeutic candidates and cutting-edge drug delivery technology to vastly improve drug targeting and safety, reduce negative impacts on the microbiome, speed the time-to-market and eliminate non-target antibiotic resistance risks. In parallel, our data science and bioinformatics partners are working hard to understand host and microbiome genetics and transcriptomics to further define the impact of our drugs on the patients immune system, microbiome and overall health. We believe this will lead us to new data, novel discoveries and potentially new diagnostics and therapeutics.
To learn more about FlightPath Biosciences, visit http://flightpath.bio/
Contact:
Matthew Tindall, President and Chief Executive Officer
415-530-1828
https://www.linkedin.com/in/matthewtindall/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.